In the goal of enhancing DC-based immunotherapy by using tumor cells-derived EVs as immune agonists of DC activation, authors depleted tumor-derived exosomes of all miRNAs and demonstrated that T-cells activated by DCs receiving these exosomes had higher perforin and cytotoxic secretions [134]. This evidence concerns the gene PRF1 and neoplasm.